{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:12:15Z","timestamp":1788894735200,"version":"build-2803163510"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10120-025-01703-w","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:56:56Z","timestamp":1767495416000},"page":"300-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibody\u2013drug conjugates in gastric cancer: clinical advances and resistance mechanisms"],"prefix":"10.1007","volume":"29","author":[{"given":"Wenke","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-3190","authenticated-orcid":false,"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"1703_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1703_CR2","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.3390\/ijerph20032149","volume":"20","author":"CB Conti","year":"2023","unstructured":"Conti CB, Agnesi S, Scaravaglio M, Masseria P, Dinelli ME, Oldani M, et al. Early gastric cancer: update on prevention, diagnosis and treatment. Int J Environ Res Public Health. 2023;20:2149.","journal-title":"Int J Environ Res Public Health"},{"key":"1703_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"W-L Guan","year":"2023","unstructured":"Guan W-L, He Y, Xu R-H. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16:57.","journal-title":"J Hematol Oncol"},{"key":"1703_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh D-Y, Ya\u00f1ez P, Bai Y, Ryu M-H, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"1703_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"1703_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"1703_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"key":"1703_CR8","doi-asserted-by":"crossref","unstructured":"Shitara K, Gumus M, Pietrantonio F, Lonardi S, De La Fouchardiere C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W (2025) Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM)+ paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable\/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. Am Soc Clin Oncol.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4002"},{"key":"1703_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","volume":"41","author":"Z Peng","year":"2021","unstructured":"Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun. 2021;41:1173\u201382.","journal-title":"Cancer Commun"},{"key":"1703_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","volume":"38","author":"CT Harris","year":"2024","unstructured":"Harris CT, Cohen S. Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies. BioDrugs. 2024;38:205\u201326. https:\/\/doi.org\/10.1007\/s40259-023-00641-2.","journal-title":"BioDrugs"},{"key":"1703_CR11","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.2217\/fon-2022-0407","volume":"18","author":"J Furlanetto","year":"2022","unstructured":"Furlanetto J, Marm\u00e9 F, Loibl S. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. Future Oncol. 2022;18:3199\u2013215. https:\/\/doi.org\/10.2217\/fon-2022-0407.","journal-title":"Future Oncol"},{"key":"1703_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315\u201337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"},{"key":"1703_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4161\/mabs.2.3.11788","volume":"2","author":"IR Correia","year":"2010","unstructured":"Correia IR. Stability of IgG isotypes in serum. MAbs. 2010;2:221\u201332. https:\/\/doi.org\/10.4161\/mabs.2.3.11788.","journal-title":"MAbs"},{"key":"1703_CR14","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","volume":"234","author":"M Abdollahpour-Alitappeh","year":"2019","unstructured":"Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, et al. Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol. 2019;234:5628\u201342. https:\/\/doi.org\/10.1002\/jcp.27419.","journal-title":"J Cell Physiol"},{"key":"1703_CR15","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.Can-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280\u201390. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-1776.","journal-title":"Cancer Res"},{"key":"1703_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/antib10040042","author":"MC Pettinato","year":"2021","unstructured":"Pettinato MC. Introduction to antibody-drug conjugates. Antibodies. 2021. https:\/\/doi.org\/10.3390\/antib10040042.","journal-title":"Antibodies"},{"key":"1703_CR17","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/s1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512\u201322. https:\/\/doi.org\/10.1016\/s1470-2045(17)30604-6.","journal-title":"Lancet Oncol"},{"key":"1703_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41392-024-02097-4","volume":"10","author":"T Zhan","year":"2025","unstructured":"Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M, et al. Digestive cancers: mechanisms, therapeutics and management. Signal Transduct Target Ther. 2025;10:24. https:\/\/doi.org\/10.1038\/s41392-024-02097-4.","journal-title":"Signal Transduct Target Ther"},{"key":"1703_CR19","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1209124.","journal-title":"N Engl J Med"},{"key":"1703_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"key":"1703_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/s0140-6736(10)61121-x","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(10)61121-x.","journal-title":"Lancet"},{"key":"1703_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/s1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18:640\u201353. https:\/\/doi.org\/10.1016\/s1470-2045(17)30111-0.","journal-title":"Lancet Oncol"},{"key":"1703_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039\u201346. https:\/\/doi.org\/10.1111\/cas.12966.","journal-title":"Cancer Sci"},{"key":"1703_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111682","volume":"183","author":"Z Xu","year":"2019","unstructured":"Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985). Eur J Med Chem. 2019;183:111682. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111682.","journal-title":"Eur J Med Chem"},{"key":"1703_CR25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/jco.22.00575","volume":"41","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol. 2023;41:816\u201325. https:\/\/doi.org\/10.1200\/jco.22.00575.","journal-title":"J Clin Oncol"},{"key":"1703_CR26","doi-asserted-by":"crossref","unstructured":"Yamaguchi K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, Chung HCC, Kawakami H, Yabusaki H, Lee J (2021) Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). Wolters Kluwer Health.","DOI":"10.1016\/j.annonc.2020.04.064"},{"key":"1703_CR27","doi-asserted-by":"publisher","first-page":"S1542","DOI":"10.1016\/j.annonc.2023.10.307","volume":"34","author":"L Shen","year":"2023","unstructured":"Shen L, Chen P, Lu J, Wan Y, Zheng Y, Ye F, et al. 172P trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced\/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial. Ann Oncol. 2023;34:S1542\u20133.","journal-title":"Ann Oncol"},{"key":"1703_CR28","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744\u201356.","journal-title":"Lancet Oncol"},{"key":"1703_CR29","doi-asserted-by":"crossref","unstructured":"Janjigian YY, Oh D-Y, Rha SY, Lee KW, Steeghs, N., Chao, Y., Di Bartolomeo, M., D\u00edez Garcia, M., Haj Mohammad, N., and Stein, A. (2022). Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced\/metastatic HER2+ gastric cancer (GC)\/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. Am Soc Clin Oncol.","DOI":"10.1200\/JCO.2022.40.4_suppl.295"},{"key":"1703_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102415","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102415.","journal-title":"EClinicalMedicine"},{"key":"1703_CR31","doi-asserted-by":"crossref","unstructured":"Liu L, Li S, Liu Z, Liu Y, Li K, Cong L, Cao F, Liu A, Liu H, Li L (2025) Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC): Updated results from the RCTS trial. Am Soc Clin Oncol.","DOI":"10.1200\/JCO.2025.43.16_suppl.4059"},{"key":"1703_CR32","doi-asserted-by":"crossref","unstructured":"Wang L, Liu L, Liu B, Sun D, Chai J (2025) Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study. Am Soc Clin Oncol.","DOI":"10.1200\/JCO.2025.43.16_suppl.e16147"},{"key":"1703_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100814","volume":"3","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Qiu MZ, Wang JF, Zhang YQ, Shen A, Yuan XL, et al. Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Cell Rep Med. 2022;3:100814. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100814.","journal-title":"Cell Rep Med"},{"key":"1703_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-025-02149-3","volume":"10","author":"X Hu","year":"2025","unstructured":"Hu X, Zhang Q, Wang L, Zhang J, Ouyang Q, Wang X, et al. ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer. Signal Transduct Target Ther. 2025;10:56. https:\/\/doi.org\/10.1038\/s41392-025-02149-3.","journal-title":"Signal Transduct Target Ther"},{"key":"1703_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21:354\u201369.","journal-title":"Nat Rev Clin Oncol"},{"key":"1703_CR36","doi-asserted-by":"crossref","unstructured":"Peng Z, Zhu H, Wang J, Han L, Chen J, Lu J, Shen L (2025) Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric\/gastro-esophageal junction (G\/GEJ) adenocarcinoma from a phase Ib\/II study. Am Soc Clin Oncol.","DOI":"10.1200\/JCO.2025.43.4_suppl.454"},{"key":"1703_CR37","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara K, Xu R-H, Ajani JA, Moran D, Guerrero A, Li R, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27:1058\u201368.","journal-title":"Gastric Cancer"},{"key":"1703_CR38","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368.","journal-title":"Lancet"},{"key":"1703_CR39","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang Y-J, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18. 2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341.","journal-title":"Nat Med"},{"key":"1703_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68411-w","volume":"14","author":"E Choi","year":"2024","unstructured":"Choi E, Shin J, Ryu MH, Kim HD, Park YS. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Sci Rep. 2024;14:17648. https:\/\/doi.org\/10.1038\/s41598-024-68411-w.","journal-title":"Sci Rep"},{"key":"1703_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"D-Y Ruan","year":"2025","unstructured":"Ruan D-Y, Liu F-R, Wei X-L, Luo S-X, Zhuang Z-X, Wang Z-N, et al. Claudin 18.2-targeting antibody\u2013drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26:227\u201338.","journal-title":"Lancet Oncol"},{"key":"1703_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.311","volume":"35","author":"J Liu","year":"2024","unstructured":"Liu J, Yu X, Zhang J, Yang J, Yue J, Sun Y, et al. 396MO anti-claudin 18.2 (CLDN18. 2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric\/gastro-esophageal junction adenocarcinoma (G\/GEJ AC): a phase I study. Ann Oncol. 2024;35:S160.","journal-title":"Ann Oncol"},{"key":"1703_CR43","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","volume":"31","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Wu HX, Luo SX, Huang WW, Liang XJ, Niu ZX, et al. The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. Nat Med. 2025;31:3037\u201346. https:\/\/doi.org\/10.1038\/s41591-025-03781-w.","journal-title":"Nat Med"},{"key":"1703_CR44","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.annonc.2025.08.2733","volume":"36","author":"J Ma","year":"2025","unstructured":"Ma J, Cao D, Zhao Q, Mendis SR, Zhang J, Coward J, et al. 2113P Phase I\/II study of claudin 18.2 ADC ATG-022 in patients with advanced gastric\/gastroesophageal junction cancer (CLINCH). Annals Oncol. 2025;36:1192.","journal-title":"Annals Oncol"},{"key":"1703_CR45","unstructured":"Yu J, Sun Y, Liu T, Guo Z, Ying J, Sun M, Wen Q, Liu Z, Zhang Y, Xia J, Ning F. Efficacy and safety of XNW27011, a Claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with Claudin 18.2 positive gastric\/gastroesophageal junction cancer: Results from ongoing phase I\/II study. Am Soc Clin Oncol."},{"key":"1703_CR46","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","volume":"99","author":"D Fong","year":"2008","unstructured":"Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290\u20135. https:\/\/doi.org\/10.1038\/sj.bjc.6604677.","journal-title":"Br J Cancer"},{"key":"1703_CR47","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3892\/etm.2017.4788","volume":"14","author":"B Wu","year":"2017","unstructured":"Wu B, Yu C, Zhou B, Huang T, Gao L, Liu T, et al. Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells. Exp Ther Med. 2017;14:1947\u201352. https:\/\/doi.org\/10.3892\/etm.2017.4788.","journal-title":"Exp Ther Med"},{"key":"1703_CR48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.11648\/j.ajcem.20210903.14","volume":"9","author":"M Shen","year":"2021","unstructured":"Shen M, Liu S, Stoyanova T. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol. 2021;9:73\u201387.","journal-title":"Am J Clin Exp Urol"},{"key":"1703_CR49","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.18632\/oncotarget.6733","volume":"7","author":"W Zhao","year":"2016","unstructured":"Zhao W, Zhu H, Zhang S, Yong H, Wang W, Zhou Y, et al. Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget. 2016;7:6136\u201345. https:\/\/doi.org\/10.18632\/oncotarget.6733.","journal-title":"Oncotarget"},{"key":"1703_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5604\/16652681.1184223","volume":"15","author":"K Sawanyawisuth","year":"2016","unstructured":"Sawanyawisuth K, Tantapotinan N, Wongkham C, Riggins GJ, Kraiklang R, Wongkham S, et al. Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma. Ann Hepatol. 2016;15:71\u201381. https:\/\/doi.org\/10.5604\/16652681.1184223.","journal-title":"Ann Hepatol"},{"key":"1703_CR51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12935-018-0589-9","volume":"18","author":"SM Zimmers","year":"2018","unstructured":"Zimmers SM, Browne EP, Williams KE, Jawale RM, Otis CN, Schneider SS, et al. TROP2 methylation and expression in tamoxifen-resistant breast cancer. Cancer Cell Int. 2018;18:94. https:\/\/doi.org\/10.1186\/s12935-018-0589-9.","journal-title":"Cancer Cell Int"},{"key":"1703_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/jcp.2008.060590","volume":"62","author":"G M\u00fchlmann","year":"2009","unstructured":"M\u00fchlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 2009;62:152\u20138. https:\/\/doi.org\/10.1136\/jcp.2008.060590.","journal-title":"J Clin Pathol"},{"key":"1703_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3892\/mco.2021.2267","volume":"14","author":"S Kushiyama","year":"2021","unstructured":"Kushiyama S, Yashiro M, Yamamoto Y, Sera T, Sugimoto A, Nishimura S, et al. Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer. Mol Clin Oncol. 2021;14:105. https:\/\/doi.org\/10.3892\/mco.2021.2267.","journal-title":"Mol Clin Oncol"},{"key":"1703_CR54","doi-asserted-by":"crossref","unstructured":"Rodon J, Wainberg ZA, Zhang M, Liu T, Liu B, Yu G, Yin Y, Zhang S, Mi Y, Li X (2024) Abstract CT038: Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study. Cancer Research 84:CT038-CT038.","DOI":"10.1158\/1538-7445.AM2024-CT038"},{"key":"1703_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3851-y","volume":"17","author":"G-d Cao","year":"2017","unstructured":"Cao G-d, Chen K, Chen B, Xiong M-m. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. BMC Cancer. 2017;17:1\u201316.","journal-title":"BMC Cancer"},{"key":"1703_CR56","doi-asserted-by":"publisher","unstructured":"Majumder A (2023) HER3: toward the prognostic significance, therapeutic potential, current challenges, and future therapeutics in different types of cancer. Cells. https:\/\/doi.org\/10.3390\/cells12212517.","DOI":"10.3390\/cells12212517"},{"key":"1703_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100790","volume":"8","author":"J Uliano","year":"2023","unstructured":"Uliano J, Corvaja C, Curigliano G, Tarantino P. Targeting HER3 for cancer treatment: a new horizon for an old target. ESMO Open. 2023;8:100790.","journal-title":"ESMO Open"},{"key":"1703_CR58","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s13046-022-02515-x","volume":"41","author":"L Gandullo-S\u00e1nchez","year":"2022","unstructured":"Gandullo-S\u00e1nchez L, Oca\u00f1a A, Pandiella A. HER3 in cancer: from the bench to the bedside. J Exp Clin Cancer Res. 2022;41:310.","journal-title":"J Exp Clin Cancer Res"},{"key":"1703_CR59","doi-asserted-by":"publisher","first-page":"7843","DOI":"10.1158\/1078-0432.Ccr-08-1064","volume":"14","author":"M Hayashi","year":"2008","unstructured":"Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 2008;14:7843\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-1064.","journal-title":"Clin Cancer Res"},{"key":"1703_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pccm.2022.12.001","volume":"1","author":"ME Larsen","year":"2023","unstructured":"Larsen ME, Lyu H, Liu B. HER3-targeted therapeutic antibodies and antibody\u2013drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors. Chin Med J Pulmonary Crit Care Med. 2023;1:11\u20137.","journal-title":"Chin Med J Pulmonary Crit Care Med"},{"key":"1703_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0862-5","volume":"17","author":"X Li","year":"2018","unstructured":"Li X, Xu Y, Ding Y, Li C, Zhao H, Wang J, et al. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer. Mol Cancer. 2018;17:1\u201314.","journal-title":"Mol Cancer"},{"key":"1703_CR62","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1172\/JCI126598","volume":"130","author":"K Haratani","year":"2020","unstructured":"Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, et al. U3\u20131402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J Clin Invest. 2020;130:374\u201388.","journal-title":"J Clin Invest"},{"key":"1703_CR63","doi-asserted-by":"crossref","unstructured":"Mok TS, Yu HA, Lim SM, Okamoto I, Perol M, Novello S, Dooms CA, Sun J-M, Kao SC-H, J\u00e4nne PA (2025) Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. Am Soc Clin Oncol.","DOI":"10.1200\/JCO.2025.43.16_suppl.8506"},{"key":"1703_CR64","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40291-024-00755-5","volume":"29","author":"RD Houvast","year":"2025","unstructured":"Houvast RD, van Duijvenvoorde M, Thijse K, de Steur WO, de Geus-Oei L-F, Crobach ASL, et al. Selecting targets for molecular imaging of gastric cancer: an immunohistochemical evaluation. Mol Diagn Ther. 2025;29:213\u201327.","journal-title":"Mol Diagn Ther"},{"key":"1703_CR65","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1038\/s41591-025-03843-z","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz S, Boni V, Kato K, Raghav KPS, Vieito M, Pallis A, et al. Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial. Nat Med. 2025;31:3504\u201313. https:\/\/doi.org\/10.1038\/s41591-025-03843-z.","journal-title":"Nat Med"},{"key":"1703_CR66","doi-asserted-by":"crossref","unstructured":"Lentz RW, Ng MC, Yong W-P, Meric-Bernstam F, Singh I, Srirangam V, Cometa J, Blanchard S, Nellore R, Shah KJ (2025) Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study. Am Soc Clin Oncol.","DOI":"10.1200\/JCO.2025.43.16_suppl.4018"},{"key":"1703_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189953","volume":"12","author":"H Danaee","year":"2017","unstructured":"Danaee H, Kalebic T, Wyant T, Fassan M, Mescoli C, Gao F, et al. Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers. PLoS ONE. 2017;12:e0189953.","journal-title":"PLoS ONE"},{"key":"1703_CR68","doi-asserted-by":"publisher","first-page":"38841","DOI":"10.18632\/oncotarget.16406","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Cheng G, Qian J, Ju H, Zhu Y, Stefano M, et al. Expression of guanylyl cyclase C in tissue samples and the circulation of rectal cancer patients. Oncotarget. 2017;8:38841.","journal-title":"Oncotarget"},{"key":"1703_CR69","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10637-017-0439-y","volume":"35","author":"K Almhanna","year":"2017","unstructured":"Almhanna K, Miron MLL, Wright D, Gracian AC, Hubner RA, Van Laethem J-L, et al. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. Invest New Drugs. 2017;35:235\u201341.","journal-title":"Invest New Drugs"},{"key":"1703_CR70","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00280-023-04507-w","volume":"91","author":"R Kim","year":"2023","unstructured":"Kim R, Leal AD, Parikh A, Ryan DP, Wang S, Bahamon B, et al. A phase I, first-in-human study of TAK-164, an antibody\u2013drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharmacol. 2023;91:291\u2013300.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1703_CR71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, et al. Antibody-drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18:51.","journal-title":"J Hematol Oncol"},{"key":"1703_CR72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.09.024","volume":"105","author":"H Saeki","year":"2018","unstructured":"Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018;105:41\u20139.","journal-title":"Eur J Cancer"},{"key":"1703_CR73","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1200\/JCO.20.02761","volume":"39","author":"I Haffner","year":"2021","unstructured":"Haffner I, Schierle K, Raim\u00fandez E, Geier B, Maier D, Hasenauer J, et al. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. J Clin Oncol. 2021;39:1468\u201378.","journal-title":"J Clin Oncol"},{"key":"1703_CR74","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdn169.","journal-title":"Ann Oncol"},{"key":"1703_CR75","doi-asserted-by":"crossref","unstructured":"Ilhan-Mutlu A, Lordick F, W\u00f6ll E (2025) Zolbetuximab and the novel biomarker claudin 18.2 in the treatment of gastroesophageal adenocarcinoma. memo-Magazine of European Medical Oncology, 1\u20138.","DOI":"10.1007\/s12254-025-01065-0"},{"key":"1703_CR76","doi-asserted-by":"publisher","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","volume":"14","author":"E Choi","year":"2024","unstructured":"Choi E, Shin J, Ryu M-H, Kim H-D, Park YS. Heterogeneity of claudin 182 expression in metastatic gastric cancer. Sci Rep. 2024;14:17648.","journal-title":"Sci Rep"},{"key":"1703_CR77","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1158\/1078-0432.CCR-16-0970","volume":"23","author":"MF Mercogliano","year":"2017","unstructured":"Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, et al. TNF\u03b1-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin Cancer Res. 2017;23:636\u201348.","journal-title":"Clin Cancer Res"},{"key":"1703_CR78","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.4049\/jimmunol.1202364","volume":"190","author":"M Shi","year":"2013","unstructured":"Shi M, Yang Z, Hu M, Liu D, Hu Y, Qian L, et al. Catecholamine-induced \u03b22-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. J Immunol. 2013;190:5600\u20138.","journal-title":"J Immunol"},{"key":"1703_CR79","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1186\/s12885-017-3851-y","volume":"17","author":"GD Cao","year":"2017","unstructured":"Cao GD, Chen K, Chen B, Xiong MM. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. BMC Cancer. 2017;17:841. https:\/\/doi.org\/10.1186\/s12885-017-3851-y.","journal-title":"BMC Cancer"},{"key":"1703_CR80","doi-asserted-by":"publisher","first-page":"657","DOI":"10.4161\/cbt.5.6.2708","volume":"5","author":"PC Liu","year":"2006","unstructured":"Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther. 2006;5:657\u201364. https:\/\/doi.org\/10.4161\/cbt.5.6.2708.","journal-title":"Cancer Biol Ther"},{"key":"1703_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054644","volume":"8","author":"J Lee","year":"2013","unstructured":"Lee J, Kim S, Kim P, Liu X, Lee T, Kim K-M, et al. A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS ONE. 2013;8:e54644.","journal-title":"PLoS ONE"},{"key":"1703_CR82","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00681","volume":"8","author":"K Yamaguchi","year":"2024","unstructured":"Yamaguchi K, Ito M, Isobe T, Koreishi S, Taguchi R, Uehara K, et al. Impact of genomic alterations on efficacy of trastuzumab deruxtecan against human epidermal growth factor receptor-2-positive advanced gastric cancer. JCO Precis Oncol. 2024;8:e2300681. https:\/\/doi.org\/10.1200\/po.23.00681.","journal-title":"JCO Precis Oncol"},{"key":"1703_CR83","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1172\/jci75200","volume":"124","author":"J Kim","year":"2014","unstructured":"Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest. 2014;124:5145\u201358. https:\/\/doi.org\/10.1172\/jci75200.","journal-title":"J Clin Invest"},{"key":"1703_CR84","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.09.024","volume":"105","author":"H Saeki","year":"2018","unstructured":"Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018;105:41\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.024.","journal-title":"Eur J Cancer"},{"key":"1703_CR85","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1200\/jco.20.02761","volume":"39","author":"I Haffner","year":"2021","unstructured":"Haffner I, Schierle K, Raim\u00fandez E, Geier B, Maier D, Hasenauer J, et al. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. J Clin Oncol. 2021;39:1468\u201378. https:\/\/doi.org\/10.1200\/jco.20.02761.","journal-title":"J Clin Oncol"},{"key":"1703_CR86","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10120-016-0599-z","volume":"20","author":"K Shoda","year":"2017","unstructured":"Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer. 2017;20:126\u201335. https:\/\/doi.org\/10.1007\/s10120-016-0599-z.","journal-title":"Gastric Cancer"},{"key":"1703_CR87","doi-asserted-by":"crossref","unstructured":"Geng W, Thomas H, Chen Z, Yan Z, Zhang P, Zhang M, Huang W, Ren X, Wang Z, Ding K (2024) Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: a comprehensive review. Eur J Pharmacol, 176725.","DOI":"10.1016\/j.ejphar.2024.176725"},{"key":"1703_CR88","doi-asserted-by":"publisher","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A (2023) Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms24119674.","DOI":"10.3390\/ijms24119674"},{"key":"1703_CR89","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/cas.13253","volume":"108","author":"H Wang","year":"2017","unstructured":"Wang H, Wang W, Xu Y, Yang Y, Chen X, Quan H, et al. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. Cancer Sci. 2017;108:1458\u201368. https:\/\/doi.org\/10.1111\/cas.13253.","journal-title":"Cancer Sci"},{"key":"1703_CR90","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/0008-5472.Can-15-1610","volume":"75","author":"KJ Hamblett","year":"2015","unstructured":"Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK, et al. SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm. Cancer Res. 2015;75:5329\u201340. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-1610.","journal-title":"Cancer Res"},{"key":"1703_CR91","doi-asserted-by":"publisher","first-page":"391","DOI":"10.7150\/jca.6470","volume":"4","author":"SC Sekhar","year":"2013","unstructured":"Sekhar SC, Kasai T, Satoh A, Shigehiro T, Mizutani A, Murakami H, et al. Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells. J Cancer. 2013;4:391\u2013401. https:\/\/doi.org\/10.7150\/jca.6470.","journal-title":"J Cancer"},{"key":"1703_CR92","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1083\/jcb.201812110","volume":"218","author":"A Kvainickas","year":"2019","unstructured":"Kvainickas A, N\u00e4gele H, Qi W, Dokl\u00e1dal L, Jimenez-Orgaz A, Stehl L, et al. Retromer and TBC1D5 maintain late endosomal RAB7 domains to enable amino acid-induced mTORC1 signaling. J Cell Biol. 2019;218:3019\u201338. https:\/\/doi.org\/10.1083\/jcb.201812110.","journal-title":"J Cell Biol"},{"key":"1703_CR93","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature14064","volume":"517","author":"HF Renard","year":"2015","unstructured":"Renard HF, Simunovic M, Lemi\u00e8re J, Boucrot E, Garcia-Castillo MD, Arumugam S, et al. Endophilin-A2 functions in membrane scission in clathrin-independent endocytosis. Nature. 2015;517:493\u20136. https:\/\/doi.org\/10.1038\/nature14064.","journal-title":"Nature"},{"key":"1703_CR94","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/0008-5472.CAN-15-1610","volume":"75","author":"KJ Hamblett","year":"2015","unstructured":"Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK, et al. SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm. Cancer Res. 2015;75:5329\u201340.","journal-title":"Cancer Res"},{"key":"1703_CR95","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1634\/theoncologist.8-5-411","volume":"8","author":"GD Leonard","year":"2003","unstructured":"Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8:411\u201324. https:\/\/doi.org\/10.1634\/theoncologist.8-5-411.","journal-title":"Oncologist"},{"key":"1703_CR96","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10555-012-9402-8","volume":"32","author":"M Yu","year":"2013","unstructured":"Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev. 2013;32:211\u201327. https:\/\/doi.org\/10.1007\/s10555-012-9402-8.","journal-title":"Cancer Metastasis Rev"},{"key":"1703_CR97","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3389\/fphar.2019.00749","volume":"10","author":"P Liu-Kreyche","year":"2019","unstructured":"Liu-Kreyche P, Shen H, Marino AM, Iyer RA, Humphreys WG, Lai Y. Lysosomal P-gp-MDR1 confers drug resistance of Brentuximab Vedotin and its cytotoxic payload monomethyl auristatin E in tumor cells. Front Pharmacol. 2019;10:749. https:\/\/doi.org\/10.3389\/fphar.2019.00749.","journal-title":"Front Pharmacol"},{"key":"1703_CR98","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1172\/jci120481","volume":"128","author":"C Szot","year":"2018","unstructured":"Szot C, Saha S, Zhang XM, Zhu Z, Hilton MB, Morris K, et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest. 2018;128:2927\u201343. https:\/\/doi.org\/10.1172\/jci120481.","journal-title":"J Clin Invest"},{"key":"1703_CR99","doi-asserted-by":"publisher","first-page":"6849","DOI":"10.7314\/APJCP.2014.15.16.6849","volume":"15","author":"AV Felipe","year":"2014","unstructured":"Felipe AV, Moraes AA, de Oliveira J, da Silva TD, Forones NM. Establishment and partial characterization of an epirubicin-resistant gastric cancer cell line with upregulated ABCB1. Asian Pac J Cancer Prev. 2014;15:6849\u201353.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1703_CR100","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8:70.","journal-title":"Signal Transduct Target Ther"},{"key":"1703_CR101","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37:208\u201320.","journal-title":"Trends Immunol"},{"key":"1703_CR102","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrc.2017.93","volume":"17","author":"MW Dewhirst","year":"2017","unstructured":"Dewhirst MW, Secomb TW. Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer. 2017;17:738\u201350.","journal-title":"Nat Rev Cancer"},{"key":"1703_CR103","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.","journal-title":"Nat Commun"},{"key":"1703_CR104","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.3390\/cancers12102969","volume":"12","author":"M Hilmi","year":"2020","unstructured":"Hilmi M, Nicolle R, Bousquet C, Neuzillet C. Cancer-associated fibroblasts: accomplices in the tumor immune evasion. Cancers. 2020;12:2969.","journal-title":"Cancers"},{"key":"1703_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.568557","volume":"10","author":"Y Miki","year":"2020","unstructured":"Miki Y, Yashiro M, Moyano-Galceran L, Sugimoto A, Ohira M, Lehti K. Crosstalk between cancer associated fibroblasts and cancer cells in scirrhous type gastric cancer. Front Oncol. 2020;10:568557.","journal-title":"Front Oncol"},{"key":"1703_CR106","first-page":"4733","volume":"20","author":"H Matsui","year":"2000","unstructured":"Matsui H, Kubochi K, Shimada A, Hasumi A. Desmoplastic response in scirrhous gastric carcinoma: imbalance between collagen synthesis and degradation. Anticancer Res. 2000;20:4733\u20138.","journal-title":"Anticancer Res"},{"key":"1703_CR107","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.7150\/jca.18466","volume":"8","author":"Z-H Zhou","year":"2017","unstructured":"Zhou Z-H, Ji C-D, Xiao H-L, Zhao H-B, Cui Y-H, Bian X-W. Reorganized collagen in the tumor microenvironment of gastric cancer and its association with prognosis. J Cancer. 2017;8:1466.","journal-title":"J Cancer"},{"key":"1703_CR108","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.Ccr-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz LM, Zou L. Molecular pathways: targeting ATR in cancer therapy. Clin Cancer Res. 2015;21:4780\u20135. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0479.","journal-title":"Clin Cancer Res"},{"key":"1703_CR109","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","volume":"145","author":"K Schlacher","year":"2011","unstructured":"Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell. 2011;145:529\u201342. https:\/\/doi.org\/10.1016\/j.cell.2011.03.041.","journal-title":"Cell"},{"key":"1703_CR110","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30:1933\u201342.","journal-title":"Nat Med"},{"key":"1703_CR111","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/ph17101338","volume":"17","author":"B Valsasina","year":"2024","unstructured":"Valsasina B, Orsini P, Terenghi C, Ocana A. Present scenario and future landscape of payloads for ADCs: focus on DNA-interacting agents. Pharmaceuticals. 2024;17:1338.","journal-title":"Pharmaceuticals"},{"key":"1703_CR112","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2174\/156652411798062368","volume":"11","author":"M Mariani","year":"2011","unstructured":"Mariani M, Shahabi S, Sieber S, Scambia G, Ferlini C. Class III \u03b2-tubulin (TUBB3): more than a biomarker in solid tumors? Curr Mol Med. 2011;11:726\u201331. https:\/\/doi.org\/10.2174\/156652411798062368.","journal-title":"Curr Mol Med"},{"key":"1703_CR113","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","volume":"122","author":"FW Hunter","year":"2020","unstructured":"Hunter FW, Barker HR, Lipert B, Roth\u00e9 F, Gebhart G, Piccart-Gebhart MJ, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020;122:603\u201312.","journal-title":"Br J Cancer"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01703-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01703-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01703-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:04:19Z","timestamp":1772553859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01703-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1703"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01703-w","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}